PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$68.97
+1.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$69.71
From 52W high−22.98%
Volume1.27M
Market cap$5.76B
P/E (TTM)—
P/S (TTM)5.0x
Div yield—
Key dataNov 4, 2026
Open
$69.71
From 52W high
−22.98%
Volume
1.27M
Market cap
$5.76B
ValuationView details →
P/E (Fwd)
36.6x
EV/EBITDA
24.5x
P/E (TTM)
—
RSI (14)
61.1
MomentumView details →
1D Return
+1.25%
YTD Return
−9.72%
SummaryUpdated Sep 1, 2026
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biopharmaceutical company founded in 1998 and headquartered in South Plainfield, New Jersey. The company went public in June 2013 and has evolved from a research-focused organization into a commercial-stage biopharmaceutical company with multiple marketed products. PTC specializes in discovering, developing, and commercializing treatments for rare diseases, with a particular focus on genetic disorders that affect small patient populations with high unmet medical needs.
Similar companies
Latest newsMore news →
PTC THERAPEUTICS, INC. reported quarterly earnings of $0.61 per share, compared with the Zacks Consensus Estimate of $0.17 per share and $0.20 per share a year earlier.7d agoPTC Therapeutics reported third-quarter 2026 revenue of $357.8 million and a net loss of $51.7 million.7d agoSangamo Therapeutics sold substantially all assets related to its gene therapy candidate ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111 million in cash at closing, up to $100 million in contingent milestones, and assumption of specified liabilities.45d ago